Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
Multiplex Assay Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by FLIA (Flow Luminescence Immunoassay)
FRCP2; Irisin; Fibronectin type III repeat-containing protein 2
(Note: Up to 8-plex in one testing reaction)
- Product No.LMN576Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- Sample TypeSerum, plasma and other biological fluids.
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.2-200ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.067 ng/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 474
US$ 492
US$ 520
US$ 556
US$ 593
US$ 648
US$ 730
Result
For more details, please contact local distributors! US$ 912 Add to Price Calculator
Specificity
This assay has high sensitivity and excellent specificity for detection of Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 85-93 | 89 |
EDTA plasma(n=5) | 98-105 | 101 |
heparin plasma(n=5) | 91-99 | 95 |
sodium citrate plasma(n=5) | 91-101 | 94 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 96-104% | 95-105% | 86-96% | 89-98% |
EDTA plasma(n=5) | 92-105% | 80-92% | 92-104% | 80-105% |
heparin plasma(n=5) | 90-97% | 81-96% | 80-89% | 83-97% |
sodium citrate plasma(n=5) | 98-105% | 94-101% | 82-97% | 79-99% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:FNDC5) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
Diabetes Research and Clinical Practice | Serum irisin levels in new-onset type 2 diabetes PubMed: 23369227 |
Journal of diabetes and its complications | Lower circulating irisin is associated with type 2 diabetes mellitus Pubmed: 23619195 |
Horm Metab Res. | Inconsistency in circulating irisin levels: what is really happening Pubmed:24459033 |
Int J Obes (Lond). | Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice Pubmed:25199621 |
Molecular and Cellular Endocrinology | Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice Pubmed:25576856 |
journal of diabetes | Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis PubMed: 25494632 |
The Journal of Maternal-Fetal & Neonatal Medicine | Maternal circulating levels of irisin in intrahepatic cholestasis of pregnancy PubMed: 26689349 |
Hormone and Metabolic Research | Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis Pubmed:27300472 |
Nature Reviews Endocrinology | Physiology and role of irisin in glucose homeostasis. pubmed:28211512 |
Journal of Molecular and Cellular Cardiology | Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice pubmed:27638193 |
Biochemical and Biophysical Research Communications | Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma pubmed:28867187 |
PLoS One | Differential actions of PPAR-α and PPAR-β/δ on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male mice Pubmed:29351550 |
International Brazilian Journal of Urology | The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer. Pubmed:29522296 |
Redox Biology | Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative … Doi: 10.1016/j.redox.2018.10.019 |
Antioxidants & redox signaling | Low serum irisin concentration is associated with poor outcomes in patients with acute pancreatitis and irisin administration protects against experimental acute … Pubmed: 31250660 |
Journal of Maternal-Fetal & Neonatal Medicine | Maternal serum, placental, and umbilical venous blood irisin levels in intrahepatic cholestasis of pregnancy Pubmed: 31590596 |
Biomed Pharmacother | Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis Pubmed: 32199226 |
Irisin Improves Autophagy of Aged Hepatocytes via Increasing Telomerase Activity in Liver Injury Pubmed: 31976032 | |
Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma Pubmed: 31976024 | |
DOMESTIC ANIMAL ENDOCRINOLOGY | The myokine Irisin: localization and effects in swine late medium and large antral ovarian follicle Pubmed: 33120167 |
Journal of Biomaterials and Tissue Engineering | The Combination of Aerobic and Resistance Exercise Induces Weight Loss via the PGC-1α/Irisin/UCP-1 Pathway |
Evaluation of a recombinant bacillus calmette-guérin vaccine expressing P39-L7/L12 of Brucella melitensis: An immunization strategy against brucellosis in BALB/c … | |
Eur Rev Med Pharmacol Sci | Salivary Irisin: potential inflammatory biomarker in recurrent apthous stomatitis patients 33755963 |
Metabolites | Pattern of Adiponectin, Osteocalcin, Irisin, FGF-21, and MCP-1 According to the Body Size Phenotype: Could They Be Markers of Metabolic Health in Mexican-Mestizo … 34822430 |
Eat Weight Disord | Time-restricted feeding prevents metabolic diseases through the regulation of galanin/GALR1 expression in the hypothalamus of mice 34370270 |
Ir J Med Sci | Eight-week exercise program improved the quality of life of Alzheimer's patients through functional, cognitive, and biochemical parameters Pubmed:35604540 |
Biomed Pharmacother | Irisin attenuates sepsis-induced cardiac dysfunction by attenuating inflammation-induced pyroptosis through a mitochondrial ubiquitin ligase-dependent … Pubmed:35653888 |
Journal of King Saud University - Science | Interaction of nitric oxide synthase and mitochondrial ATP-sensitive potassium channels in protective impacts of combination therapy with irisin … |
Catalog No. | Related products for research use of Rattus norvegicus (Rat) Organism species | Applications (RESEARCH USE ONLY!) |
RPN576Ra01 | Recombinant Fibronectin Type III Domain Containing Protein 5 (FNDC5) | Positive Control; Immunogen; SDS-PAGE; WB. |
SEN576Ra | ELISA Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMN576Ra | Multiplex Assay Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |